Cargando…

Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma

BACKGROUND: The advent of molecular medicine may allow for individualized cancer prognostication, which should enable better clinical management and, hopefully, improve patient outcomes. A 31-gene expression profile (31-GEP) test is currently available for patients diagnosed with cutaneous melanoma;...

Descripción completa

Detalles Bibliográficos
Autores principales: Dubin, Danielle P., Dinehart, Scott M., Farberg, Aaron S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872504/
https://www.ncbi.nlm.nih.gov/pubmed/31359351
http://dx.doi.org/10.1007/s40257-019-00464-4
_version_ 1783472497170055168
author Dubin, Danielle P.
Dinehart, Scott M.
Farberg, Aaron S.
author_facet Dubin, Danielle P.
Dinehart, Scott M.
Farberg, Aaron S.
author_sort Dubin, Danielle P.
collection PubMed
description BACKGROUND: The advent of molecular medicine may allow for individualized cancer prognostication, which should enable better clinical management and, hopefully, improve patient outcomes. A 31-gene expression profile (31-GEP) test is currently available for patients diagnosed with cutaneous melanoma; this test helps inform patients’ individual treatment plans, especially when combined with traditional biomarkers. OBJECTIVE: The objective of this study was to review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test. METHODS: A review of seven development and validation studies for the 31-GEP test was conducted. The respective strengths and weaknesses of each study were applied to the level of evidence criteria from major organizations that publish guidelines for melanoma management: American Joint Committee on Cancer, National Comprehensive Cancer Network, and American Academy of Dermatology. RESULTS: Evaluating each study led to classifying the 31-GEP test as level I/II, I–IIIB, and IIA according to American Joint Committee on Cancer, National Comprehensive Cancer Network, and American Academy of Dermatology criteria, respectively. This stands in contrast to the official unrated status conferred by the American Joint Committee on Cancer and National Comprehensive Cancer Network and the II/IIIC rating designated by the American Academy of Dermatology. CONCLUSIONS: Differences between the authors’ findings and official published ratings may be attributed to chronological issues, as many of the studies were not yet published when the aforementioned organizations conducted their reviews. There was also difficulty in applying the National Comprehensive Cancer Network criteria to this prognostic test, as their guidelines were intended for evaluation of predictive markers. Nevertheless, based upon the most current data available, integration of the 31-GEP test into clinical practice may be warranted in certain clinical situations.
format Online
Article
Text
id pubmed-6872504
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Springer International Publishing
record_format MEDLINE/PubMed
spelling pubmed-68725042019-12-05 Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma Dubin, Danielle P. Dinehart, Scott M. Farberg, Aaron S. Am J Clin Dermatol Evidence-Based Review Article BACKGROUND: The advent of molecular medicine may allow for individualized cancer prognostication, which should enable better clinical management and, hopefully, improve patient outcomes. A 31-gene expression profile (31-GEP) test is currently available for patients diagnosed with cutaneous melanoma; this test helps inform patients’ individual treatment plans, especially when combined with traditional biomarkers. OBJECTIVE: The objective of this study was to review the current literature and establish the level of evidence for a cutaneous melanoma 31-GEP test. METHODS: A review of seven development and validation studies for the 31-GEP test was conducted. The respective strengths and weaknesses of each study were applied to the level of evidence criteria from major organizations that publish guidelines for melanoma management: American Joint Committee on Cancer, National Comprehensive Cancer Network, and American Academy of Dermatology. RESULTS: Evaluating each study led to classifying the 31-GEP test as level I/II, I–IIIB, and IIA according to American Joint Committee on Cancer, National Comprehensive Cancer Network, and American Academy of Dermatology criteria, respectively. This stands in contrast to the official unrated status conferred by the American Joint Committee on Cancer and National Comprehensive Cancer Network and the II/IIIC rating designated by the American Academy of Dermatology. CONCLUSIONS: Differences between the authors’ findings and official published ratings may be attributed to chronological issues, as many of the studies were not yet published when the aforementioned organizations conducted their reviews. There was also difficulty in applying the National Comprehensive Cancer Network criteria to this prognostic test, as their guidelines were intended for evaluation of predictive markers. Nevertheless, based upon the most current data available, integration of the 31-GEP test into clinical practice may be warranted in certain clinical situations. Springer International Publishing 2019-07-29 2019 /pmc/articles/PMC6872504/ /pubmed/31359351 http://dx.doi.org/10.1007/s40257-019-00464-4 Text en © The Author(s) 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Evidence-Based Review Article
Dubin, Danielle P.
Dinehart, Scott M.
Farberg, Aaron S.
Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title_full Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title_fullStr Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title_full_unstemmed Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title_short Level of Evidence Review for a Gene Expression Profile Test for Cutaneous Melanoma
title_sort level of evidence review for a gene expression profile test for cutaneous melanoma
topic Evidence-Based Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6872504/
https://www.ncbi.nlm.nih.gov/pubmed/31359351
http://dx.doi.org/10.1007/s40257-019-00464-4
work_keys_str_mv AT dubindaniellep levelofevidencereviewforageneexpressionprofiletestforcutaneousmelanoma
AT dinehartscottm levelofevidencereviewforageneexpressionprofiletestforcutaneousmelanoma
AT farbergaarons levelofevidencereviewforageneexpressionprofiletestforcutaneousmelanoma